Glaxo-Novartis JV ‘On Track’ To Launch; J&J ‘Well Through’ Most Of OTC Remediation
This article was originally published in The Tan Sheet
Executive Summary
Glaxo’s consumer product sales will be around 25% of the $40 billion total annual revenues the firm projects following the closure of its Novartis agreement. J&J CEO Alex Gorsky sees light at the end of the tunnel for remediation of the firm’s OTC manufacturing under a consent decree with FDA.